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Introduction
Chemotherapy is the standard treatment for patients with metastatic colorectal cancer (CRC); however, most patients ultimately develop drug resistance. Oxaliplatin is an efficacious third-generation platinum-based compound that is commonly used to treat CRC (Meyerhardt and Mayer 2005) . This result supports the clinical significance of oxaliplatin-containing regimens in CRC management. Nevertheless, despite this demonstrated efficacy, virtually all metastatic CRC eventually become resistant to oxaliplatin, with a median disease progression period of 8 months (Goldberg et al. 2004 ). However, the mechanism underlying drug resistance to oxaliplatin remains unknown.
Stanniocalcin (STC), which comprised STC1 and STC2, is a glycoprotein hormone that was originally discovered in fish and has been implicated in calcium and phosphate homeostasis (Wagner et al. 1998) . In mammals, STC2 is widely expressed in both developing and adult tissues (Law and Wong 2010; Jepsen et al. 2015) .
Recently, researchers have suggested the involvement of STC2 in the progression of many types of cancer (Hashemzadeh et al. 2014 ). Higher STC2 expression levels have been detected in gastric cancers relative to normal mucosa and have also been closely associated with lymph node metastasis and venous tumor invasion (Yokobori et al. 2010 ). STC2 secretion from colon cancer cells has been confirmed in a simulated model of the tumor microenvironment (Zeng et al. 2013) , suggesting an important role of STC2 in the development and progression of colon cancer. Despite these pioneering studies, the clinical significance and molecular mechanism of STC2 in D r a f t cancers still remain controversial and their further elucidation is warranted. Moreover, the association of STC2 with oxaliplatin resistance in colon cancer has not yet been investigated; therefore, we speculated that STC2 regulates oxaliplatin-induced multidrug resistance (MDR) in CRC.
P-glycoprotein (P-gp), a 170-kDa protein encoded by the human multidrug-resistance 1 (MDR1) gene, belongs to the ATP-binding cassette (ABC)
superfamily of membrane transporters (Loo and Clarke 2005) . Among these membrane transporters, P-gp plays the most important role in reducing the intracellular accumulation of anticancer drugs (Gottesman and Ling 2006). The P-gp protein is found in high concentrations at the apical surfaces of colonic epithelial cells and is also known to mediate drug resistance in CRC (Kuan et al. 2011) . Researchers have confirmed that in certain tumors, microenvironmental factors including hypoxia can induce P-gp upregulation as part of a pathway that functions during resistance to chemotherapeutics (Comerford et al. 2002) . Various chemically unrelated anticancer drugs, including paclitaxel, doxorubicin, and vinblastine, are P-gp substrates (Szakacs et al. 2006) . Recently, oxaliplatin was also reported to upregulate P-gp expression in drug-resistant CRC cells (Wang et al. 2015) .
Cancer signaling pathways associated with MDR including the phosphoinositide 3-kinase (PI3K)/Akt pathway, are known to play pivotal roles in the regulation of drug-induced functional activities such as DNA damage-induced apoptosis, inhibition of cell growth, and anti-metastatic progression (Persons et al. 1999; Wang et al. 2000) .
PI3K/Akt influenced the development of MDR in colon cancer (Wang et al. 2014 ).
D r a f t
Recent evidence has emphasized the interplay between PI3K/Akt signaling and P-gp-mediated MDR in CRC (Jiang and Liu 2008; Kuo et al. 2011) . Secreted STC1
promoted the metastatic potential of breast cancer cells via PI3K/Akt activation (Murai et al., 2014) . However, the effect of STC2 on PI3K/Akt signaling pathway activation in the context of MDR colon cancer remains unknown.
In the present study, we hypothesized that STC2 regulates PI3K/Akt signaling pathway and therefore oxaliplatin-induced and P-gp-mediated MDR in colon cancer.
Materials and Methods

Cell lines and the in vitro chemoresistance model
The human CRC cell lines HT29, RKO, and HCT116 were obtained from the American Type Culture Collection (ATCC, Manassas, VA, USA). The oxaliplatin-resistant cell lines HT29-OxR, RKO-OxR, and HCT116-OxR were developed as previously described (Yang et al. 2006 
Western blot analysis
The expression levels of several proteins were detected by Western blot analysis.
Proteins were separated using 10% sodium dodecyl sulfate-polyacrylamide gel electrophoresis and transferred onto a polyvinylidene fluoride (PVDF) membrane at 100 V for 1 h. Subsequently, the membrane was incubated in TBS/T buffer [20 mM
Tris-HCl (pH 7.6), 150 mM NaCl, 0.1% Tween-20] containing 5% non-fat milk at room temperature for 2 h. Specific primary antibodies including rabbit anti-human STC2 (diluted 1:500), rabbit anti-human P-gp (diluted 1:1000), rabbit anti-human PI3K (diluted 1:1000), rabbit anti-human p-Akt (diluted 1:1000), and mouse anti-human GAPDH (diluted 1:2000) were from Santa Cruz Biotechnology. All antibodies were diluted in TBST buffer [50 mM Tris-HCl (pH 7.4), 150 mM NaCl, 0.1% Tween-20] with which the PVDF membranes were incubated at 4ºC overnight.
Subsequently, the PVDF membranes were incubated with the corresponding horseradish peroxidase-conjugated secondary antibodies for 60 min at room temperature. Signal detection was performed using an enhanced chemiluminescence reagent (Amersham Biosciences, Piscataway, NJ, USA).
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Apoptosis determination
Annexin V-propidium iodide (PI) staining (Beyotime Biotechnology, Jiangsu China) was analyzed using flow cytometry. Cells were collected and washed twice with phosphate-buffered saline (PBS), followed by resuspension in 250 µl binding buffer. Five microliter FITC-annexin V and 10 µl PI (20 µg/ml) were added to each 100-µl cell suspension, and the cells were incubated at room temperature for 15 min.
Subsequently, 400 µl PBS was added to the cell suspensions and the samples were analyzed by flow cytometry (Becton-Dickinson, Franklin Lakes, NJ, USA).
To measure caspase-3 activity, cells were seeded into 12-well plates at a density of 1 × 10 5 cells/well, and caspase-3-like protease activity in cell lysates was measured using a colorimetric caspase-3 assay (Beyotime Biotechnology). Caspase-3 activity is expressed in values of optical density at 405 nm (OD 405 ).
Detection of P-gp function
Rhodamine-123 efflux was used to detect the P-gp function of cells. Cells were cultured in 6-well plates; at 70-80% confluence, rhodamine-123 (Sigma) was added to the cells at a final concentration of 0.25 µg/ml and incubated at 37°C for 1 h. Cells were washed 3 times with PBS at 4°C and re-suspended at 5-10 × 10 5 cells/ml in PBS. Transepithelial transport of rhodamine-123
Transepithelial electrical resistance (TEER) of CRC-OxR cell monolayers cultured on a transwell chamber was monitored 24 h prior to transport studies using a Millicell ERS testing device (Millipore, Bedford, MA). The monolayers with a TEER of more than 250 Ω·cm 2 were used for transport studies. Prior to the addition of rhodamine-123, the monolayers were rinsed twice and then incubated in Hanks' balanced salt solution containing 25 mM HEPES and 25 mM glucose (HBSS buffer, pH 7.4). Rhodamine-123 was placed either on the apical (1.5 ml) side at a concentration of 5 µM and measured on the opposite side to the placed site at 37 °C periodically for 120 min. The transepithelial transport of rhodamine-123 across cell monolayers was determined fluorometrically using the Shimadzu fluorescence spectrophotometer RF-5000 (Tokyo, Japan).
Statistical analysis
Data are presented as the mean ± standard error of the mean (SEM). An independent sample t test was used to assess significant differences among continuous variables. A one-way analysis of variance followed by Tukey's test was used for multiple comparisons. All calculations were performed using the Statistical Package for the Social Sciences (SPSS) software, version 11.0 (SPSS Inc., Chicago, IL, USA).
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Differences with P values of <0.05 were considered to be statistically significant.
Results
STC2 is overexpressed in oxaliplatin-resistant CRC cells
We compared STC2 protein expression and secretion profiles of the three parental (chemonaïve) CRC cell lines HT29, HCT116, and RKO with those of their oxaliplatin-resistant derivative cells. STC2 expression was elevated in all three oxaliplatin-resistant cell lines (Fig. 1A) . We also detected elevated STC2 secretion in all three chemoresistant cell lines compared with that seen in the parental cells (Fig.   1B ). Because all three oxaliplatin-resistant CRC cell lines secreted greater amounts of STC2, we hypothesized that secreted STC2 plays a role in the development of acquired resistance to oxaliplatin in CRC cells.
STC2 induces oxaliplatin resistance in CRC cells
To confirm the functional role of STC2 in the induction of chemoresistance, the levels of STC2 in parental HCT116-OxR and HCT116 cells were altered using STC2-shRNA and exogenous STC2 protein, respectively. We successfully silenced STC2 expression and secretion ( Fig. 2A-B) . Decreased STC2 expression resulted in a dose-dependent increase in the sensitivity of HCT116-OxR cells to oxaliplatin treatment ( Fig. 2C-D) . We also detected the effect of STC2-shRNA on the survival of chemonaïve HCT116 cells (supplementary materials). Western blot analysis of STC2 expression in HCT116 cells (Fig. S1A-B) showed that STC2-shRNA had no effect on D r a f t the sensitivity to oxaliplatin treatment ( Fig. S1C-D) . Conversely, treatment with recombinant STC2 protein (10 pg/ml) reduced both the apoptosis frequency and caspase-3 activity (Fig. 3A-B ).
Correlation between P-gp and STC2 in oxaliplatin-resistant cells
During the development of chemoresistance to oxaliplatin, cancer cells likely acquire an enhanced ability to transport the drug outside the cells; this results in the suppression of chemotherapeutic cytotoxicity. To confirm the relationship between P-gp and STC2 with regard to chemoresistance induction in CRC, we first analyzed P-gp protein expression in three parental CRC-OxR cell lines, namely HT29-OxR, HCT116-OxR, and RKO-OxR. P-gp was upregulated in all three CRC-OxR cell lines (Fig. 4A) . To further confirm the regulatory effect of STC2 on P-gp expression, cells
were treated with STC2-shRNA. Compared with N-shRNA, STC2-shRNA significantly downregulated P-gp expression in the HCT116-OxR line (Fig. 4B ). The function of P-gp was detected by the concentration and apical to basolateral transport of rhodamine-123. As shown in Fig. 4C and D, STC2-shRNA reversed the P-gp effect on drug efflux and on the apical to basolateral transport (P < 0.01). 
Discussion
Metastatic CRC leads to the death of 50,000 patients annually in the USA because of primary or acquired resistance to chemotherapy (Davies and Goldberg 2008).
Therefore, it is critical to delineate drug resistance mechanisms to commonly used therapeutic agents, such as oxaliplatin, to improve the survival of patients with CRC. research into MDR reversal in cancers is primarily aimed at identifying reversal agents that target P-gp. P-gp is upregulated via the activation of the NF-κB signaling pathway (Liu et al. 2014) . Glucosylceramide synthase upregulates P-gp (product of MDR1) expression to control anticancer drug resistance through the cSrc and β-catenin signaling pathways (Liu et al. 2010) . A previous study has found that the transduction of HCT15 and HCT116 human colon carcinoma cell lines with human TNF and IL-2 reversed MDR (Stein et al. 1996) . According to our present data, STC2
positively regulated P-gp expression and increased oxaliplatin efflux from HCT116 cells. Therefore, it can be suggested that the upregulation of the STC2/P-gp pathway is involved in the oxaliplatin-resistance mechanism of CRC cells.
PI3K/Akt activity has been suggested to play a regulatory role in the MDR of cancers (Abdul-Ghani et al. 2006) . Certain drugs reverse MDR in cancers by inhibiting the PI3K/Akt signaling pathway (Choi et al. 2008; Cordo Russo et al. 2008 ).
For instance, tamoxifen reverses P-gp-mediated MDR in gastric cancer cells by inhibiting the PI3K/Akt signaling pathway (Mao et al. 2014) . Furthermore, PI3K/Akt D r a f t pathway inhibition has been shown to block drug efflux from HT29RDB colon carcinoma cells (Abdul-Ghani et al. 2006) . Consistent with previous findings, the present research shows that PI3K-shRNA and Akt-shRNA reversed the effects of STC2 on MDR in CRC. PI3K-shRNA and Akt-shRNA also inhibited STC2-induced P-gp expression. In the present study, we noted that the specific effect of STC2 on oxaliplatin resistance was mediated through a P-gp and PI3K/Akt signaling pathway-induced mechanism.
In conclusion, our study shows that STC2 overexpression is a critical component of the mechanism by which CRC cells become resistant to the cytotoxic effects of oxaliplatin. This resistance-promoting effect is mediated by PI3K/Akt and P-gp 
